Market Overview

Sagent Pharmaceuticals Announces the Launch of Vancomycin Hydrochloride for Injection, USP

SCHAUMBURG, Ill., Sept. 28, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the launch of Vancomycin Hydrochloride for Injection, USP, an anti-infective, in a 5 gram pharmacy bulk package presentation. According to IMS, for the 12 months ending June 2012, the US market for Vancomycin Hydrochloride for Injection, USP approximated $186 million of which about fifty percent of the sales was pharmacy bulk packages. As with all products in Sagent's portfolio, Vancomycin features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

About Vancomycin Hydrochloride for Injection, USP

Vancomycin Hydrochloride for Injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta lactam-resistant) staphylococci, for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for the infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.

The package insert, available at www.sagentpharma.com, contains the indications, complete side effect profile, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605
 

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters